Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-...

Prof Pier Conte speaks to ecancer at ASCO 2024 about a phase III randomised trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
He explains that patients were split 1:1 between avelumab (an immune checkpoint inhibitor) or observation.
Prof Conte reports that the primary endpoint of DFS was not met but that the difference in OS was statistically significant in favour of avelumab.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php